CRO Revenues are Expected to Increase

According to this article in in-PharmaTechnologist.com a recent study conducted by Turner Investment Partners reveals that while CROs are in demand across the whole pharma sector, they will be particularly important to smaller scale bio-pharmaceutical companies as they invest in new drug testing.

The article also details that 30% of CROs revenue come from biotech firms, which indicates that there will be heavy competition from the estimated 500 CROs around the world. Turner Investment Partners estimates that CROs will become part of up to 50% of all drug development projects at the clinical stage and pre-clinical stage within the next couple of years.